Loading...
•
Mar 31, 2023
Cardinal Health Q3 2023 Earnings Report
Cardinal Health's Q3 2023 earnings were positively influenced by the Pharmaceutical segment, while the Medical segment faced challenges. The company raised its full-year non-GAAP EPS and adjusted free cash flow guidance, reflecting confidence in its performance and strategic initiatives.
Key Takeaways
Cardinal Health reported a 13% increase in revenue to $50.5 billion for Q3 2023, driven by growth in the Pharmaceutical segment. GAAP operating earnings were $572 million, and GAAP diluted EPS was $1.34. Non-GAAP operating earnings increased by 11% to $606 million, and non-GAAP diluted EPS rose by 20% to $1.74. The company raised its full-year non-GAAP EPS and adjusted free cash flow guidance.
Revenue increased by 13% to $50.5 billion, driven by growth in the Pharmaceutical segment.
GAAP operating earnings were $572 million, with a GAAP diluted EPS of $1.34.
Non-GAAP operating earnings increased by 11% to $606 million, and non-GAAP diluted EPS increased by 20% to $1.74.
Fiscal year 2023 non-GAAP EPS guidance was raised and narrowed to $5.60 to $5.80, with adjusted free cash flow guidance also raised and narrowed to $2.0 to $2.3 billion.
Cardinal Health
Cardinal Health
Forward Guidance
The company raised and narrowed its fiscal year 2023 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $5.60 to $5.80, from $5.20 to $5.50.
Positive Outlook
- Fiscal year 2023 non-GAAP EPS guidance raised and narrowed to $5.60 to $5.80, from $5.20 to $5.50.
- Fiscal year 2023 adjusted free cash flow guidance raised and narrowed to $2.0 to $2.3 billion, from $1.5 to $2.0 billion
- Fiscal year 2023 Pharmaceutical segment profit outlook updated to 10.5% to 12% growth, from 4% to 6.5% growth.
- Interest and other in the range of $95 to $105 million.
- Adjusted free cash flow of $2.0 to $2.3 billion.
Challenges Ahead
- Medical segment profit outlook to a decline of approximately 50%, from flat to a decline of 20%.
- Non-GAAP effective tax rate of 22% to 23%.
- Diluted weighted average shares outstanding of 262 to 263 million.
- Capital expenditures of ~$450 million.
- Company does not provide forward-looking guidance on a GAAP basis as certain financial information is not available and cannot be reasonably estimated.